[go: up one dir, main page]

WO1990007862A3 - Production et selection de proteines et de polypeptides nouveaux de liaison a l'adn - Google Patents

Production et selection de proteines et de polypeptides nouveaux de liaison a l'adn Download PDF

Info

Publication number
WO1990007862A3
WO1990007862A3 PCT/US1990/000024 US9000024W WO9007862A3 WO 1990007862 A3 WO1990007862 A3 WO 1990007862A3 US 9000024 W US9000024 W US 9000024W WO 9007862 A3 WO9007862 A3 WO 9007862A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
binding
selection
binding proteins
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1990/000024
Other languages
English (en)
Other versions
WO1990007862A2 (fr
Inventor
Robert Charles Ladner
Sonia Kosow Guterman
Rachel Baribault Kent
Arthur Charles Ley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protein Engineering Corp
Original Assignee
Protein Engineering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Engineering Corp filed Critical Protein Engineering Corp
Priority to AT90902453T priority Critical patent/ATE191746T1/de
Priority to EP90902453A priority patent/EP0452413B1/fr
Priority to DE69033506T priority patent/DE69033506D1/de
Publication of WO1990007862A2 publication Critical patent/WO1990007862A2/fr
Publication of WO1990007862A3 publication Critical patent/WO1990007862A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/73—Expression systems using phage (lambda) regulatory sequences
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Insects & Arthropods (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

On produit des protéines nouvelles de liaison à l'ADN, notamment des répresseurs de l'expression du gène, par la modification de gènes connus pour coder pour des protéines se liant à l'ADN et la sélection de protéines se liant la séquence cible d'ADN désirée. On utilise un vecteur de sélection nouveau pour réduire les artefacts. On obtient des protéines hétérooligomériques se liant à une séquence cible d'ADN qui n'est pas nécessairement palindromique, par divers procédés, par exemple, la modification pour obtenir des protéines se liant à des formes palindromiques de la demi-cible et l'hétérodimérisation pour obtenir une protéine se liant à l'ensemble de la cible asymétrique.
PCT/US1990/000024 1989-01-06 1990-01-05 Production et selection de proteines et de polypeptides nouveaux de liaison a l'adn Ceased WO1990007862A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AT90902453T ATE191746T1 (de) 1989-01-06 1990-01-05 Herstellung und selektion von dna- bindungsproteinen und polypeptiden
EP90902453A EP0452413B1 (fr) 1989-01-06 1990-01-05 Production et selection de proteines et de polypeptides nouveaux de liaison a l'adn
DE69033506T DE69033506D1 (de) 1989-01-06 1990-01-05 Herstellung und selektion von dna-bindungsproteinen und polypeptiden

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US293,980 1989-01-06
US07/293,980 US5096815A (en) 1989-01-06 1989-01-06 Generation and selection of novel dna-binding proteins and polypeptides

Publications (2)

Publication Number Publication Date
WO1990007862A2 WO1990007862A2 (fr) 1990-07-26
WO1990007862A3 true WO1990007862A3 (fr) 1990-09-07

Family

ID=23131376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/000024 Ceased WO1990007862A2 (fr) 1989-01-06 1990-01-05 Production et selection de proteines et de polypeptides nouveaux de liaison a l'adn

Country Status (9)

Country Link
US (1) US5096815A (fr)
EP (1) EP0452413B1 (fr)
JP (1) JPH04504052A (fr)
AT (1) ATE191746T1 (fr)
AU (1) AU4958890A (fr)
CA (1) CA2045516A1 (fr)
DE (1) DE69033506D1 (fr)
IL (1) IL92957A0 (fr)
WO (1) WO1990007862A2 (fr)

Families Citing this family (312)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134087A1 (en) * 1988-09-02 2006-06-22 Dyax Corp. ITI-D1 Kunitz domain mutants as hNE inhibitors
GB8901676D0 (en) * 1989-01-26 1989-03-15 Ici Plc Regulation of gene expression
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
SG65593A1 (en) * 1990-02-15 1999-06-22 Dana M Fowlkes Totally synthetic affinity reagents
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
ATE126535T1 (de) * 1990-04-05 1995-09-15 Roberto Crea ''walk-through''-mutagenese.
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5258289A (en) * 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
US5578444A (en) 1991-06-27 1996-11-26 Genelabs Technologies, Inc. Sequence-directed DNA-binding molecules compositions and methods
US5726014A (en) * 1991-06-27 1998-03-10 Genelabs Technologies, Inc. Screening assay for the detection of DNA-binding molecules
JP3169610B2 (ja) * 1991-06-27 2001-05-28 ジーンラブズ テクノロジーズ，インコーポレイテッド Ｄｎａ結合分子の検出のためのスクリーニングアッセイ
DE69333669T2 (de) * 1992-03-16 2006-03-09 Wohlstadter, Jacob N. Mutagenese und selektionsmethoden in den selben wirtszellen
HU214698B (hu) * 1992-04-09 1998-06-29 Gyógyszerkutató Intézet Kft. Eljárás rekombináns deszulfátó-hirudin HV-1 peptidek előállítására
US5747449A (en) * 1992-07-13 1998-05-05 Corvas International, Inc. Bovine pancreatic trypsin inhibitor derived inhibitors of factor XA
EP0671944A4 (fr) * 1992-09-25 1996-07-24 Corvas Int Inc Inhibiteurs de complexe facteur viia-thromboplastine tissulaire derives d'un inhibiteur de trypsine pancreatique de bovin.
US20030194807A1 (en) * 1992-11-02 2003-10-16 Roberto Crea Walk-through mutagenesis
US6255059B1 (en) 1993-03-31 2001-07-03 Cadus Pharmaceutical Corporation Methods for identifying G protein coupled receptor effectors
US7235648B1 (en) 1993-03-31 2007-06-26 Cadus Technologies, Inc. Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US7416881B1 (en) * 1993-03-31 2008-08-26 Cadus Technologies, Inc. Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US6100042A (en) * 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US6864060B1 (en) 1993-03-31 2005-03-08 Cadus Technologies, Inc. Yeast cells expressing modified G proteins and methods of use therefor
US20030054402A1 (en) * 1993-03-31 2003-03-20 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
US5789184A (en) * 1993-03-31 1998-08-04 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
WO1994025609A1 (fr) * 1993-04-28 1994-11-10 Hybritech Incorporated Procede de production de regions regulatrices optimalisees affectant l'expression et le ciblage des proteines
US5712366A (en) * 1993-05-25 1998-01-27 The United States Of America As Represented By The Secretary Of The Army Fabrication of nanoscale materials using self-assembling proteins
US6140466A (en) * 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6242568B1 (en) * 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US20050084885A1 (en) * 1994-01-18 2005-04-21 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6184205B1 (en) * 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
ATE524545T1 (de) 1994-08-20 2011-09-15 Gendaq Ltd Verbesserungen bei oder im zusammenhang mit bindeproteinen zur erkennung von dna
US6465253B1 (en) * 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5885577A (en) * 1994-09-21 1999-03-23 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
CZ85597A3 (cs) * 1994-09-21 1998-01-14 Cytogen Corporation Peptidy
US20030104361A1 (en) 1997-09-29 2003-06-05 Susan Weininger Method of detection of nucleic acids with a specific sequence composition
US5871902A (en) * 1994-12-09 1999-02-16 The Gene Pool, Inc. Sequence-specific detection of nucleic acid hybrids using a DNA-binding molecule or assembly capable of discriminating perfect hybrids from non-perfect hybrids
WO1996023879A1 (fr) * 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Corps agglutinants - multiplicite de proteines capables de lier diverses petites molecules
US5789538A (en) * 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US6309820B1 (en) 1995-04-07 2001-10-30 University Of North Carolina At Chapel Hill Polypeptides having a functional domain of interest and methods of identifying and using same
CA2217641A1 (fr) 1995-04-07 1996-10-10 Cytogen Corporation Polypeptides presentant un domaine fonctionnel important, et leurs procedes d'identification et d'utilisation
CA2222140C (fr) * 1995-06-15 2010-11-23 Introgene B.V. Systemes d'empaquetage pour adenovirus recombinant chez l'homme, destine a la therapie genique
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
ATE239799T1 (de) 1995-09-07 2003-05-15 Novozymes As Nachweis der aktivität von enzymen für detergenzien durch phagen.
EP0862651A2 (fr) * 1995-10-16 1998-09-09 Chiron Corporation Procede de criblage pour la recherche de facteurs qui modulent l'expression genique
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US20040023327A1 (en) * 1995-12-07 2004-02-05 Short Jay M. End selection in directed evolution
US20030219752A1 (en) * 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US7018793B1 (en) 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US6537776B1 (en) * 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US20020164580A1 (en) * 1995-12-07 2002-11-07 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6361974B1 (en) * 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6764835B2 (en) * 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
CA2238995A1 (fr) * 1995-12-18 1997-06-26 Praecis Pharmaceuticals Incorporated Procedes d'identification de composes se liant a une cible
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6011137A (en) * 1996-04-03 2000-01-04 University Of North Carolina At Chapel Hill Identification and isolation of novel polypeptides having WW domains and methods of using same
US7279548B2 (en) * 1996-04-03 2007-10-09 Cytogen Corporation Identification and isolation of novel polypeptides having WW domains and methods of using same
AU2681997A (en) 1996-04-26 1997-11-19 Children's Medical Center Corporation Non-invasive enzyme screen for tissue remodelling-associated conditions
US6800726B1 (en) 1996-11-01 2004-10-05 Pioneer Hi-Bred International, Inc. Proteins with increased levels of essential amino acids
AU728086B2 (en) * 1996-11-01 2001-01-04 Pioneer Hi-Bred International, Inc. Proteins with enhanced levels of essential amino acids
EP1780277A1 (fr) 1997-01-15 2007-05-02 Yeda Research And Development Company, Ltd. Protéines liant le récepteur 1 d'IFN, ADN codant ces protéines et procédé pour moduler la réponse cellulaire aux interférons
US6462070B1 (en) 1997-03-06 2002-10-08 The General Hospital Corporation Photosensitizer conjugates for pathogen targeting
AU743827B2 (en) 1997-04-09 2002-02-07 Intellect Neurosciences, Inc. Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
GB9710809D0 (en) * 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
WO1998055611A1 (fr) * 1997-06-06 1998-12-10 Regents Of The University Of Michigan Element de reponse a la neureguline et ses utilisations
US20050096288A1 (en) * 1997-06-13 2005-05-05 Aragene, Inc. Lipoproteins as nucleic acid vectors
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
US6610497B1 (en) * 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
KR20010041088A (ko) * 1998-02-20 2001-05-15 게놈 다이내믹스 인코포레이티드 아연-핑거 클래스의 ｄｎａ-결합 단백질의 디자인 방법
ES2341926T3 (es) * 1998-03-02 2010-06-29 Massachusetts Institute Of Technology Poliproteinas con dedos de cinc que tienen enlazadores mejorados.
DE69932813D1 (de) 1998-03-17 2006-09-28 Gendaq Ltd Nukleinsäurebindungsproteine
DE1068357T1 (de) 1998-03-30 2001-07-19 Northwest Biotherapeutics, Inc. Therapeutische und diagnostische anwendungen welche auf der rolle von cxcr-4 in der tumorgenese basieren
US6355473B1 (en) 1998-05-06 2002-03-12 Cadus Pharmaceutical Corp. Yeast cells having mutations in stp22 and uses therefor
US6733991B1 (en) * 1998-05-08 2004-05-11 Osi Pharmaceuticals, Inc. AGS proteins and nucleic acid molecules and uses therefor
US6746852B1 (en) 1998-05-08 2004-06-08 Osi Pharmaceuticals, Inc. AGS proteins and nucleic acid molecules and uses thereof
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
US7081360B2 (en) * 1998-07-28 2006-07-25 Cadus Technologies, Inc. Expression of G protein-coupled receptors with altered ligand binding and/or coupling properties
US7273747B2 (en) * 1998-08-27 2007-09-25 Cadus Technologies, Inc. Cell having amplified signal transduction pathway responses and uses therefor
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
MXPA01003770A (es) 1998-10-13 2002-05-06 Univ Georgia Res Found Peptidos bioactivos estabilizados, y metodos de identificacion, sintesis y uso de los mismos.
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6251605B1 (en) 1998-10-27 2001-06-26 Cadus Pharmaceutical Corporation Yeast cells having mutations in Cav1 and uses therefor
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
WO2000031261A2 (fr) * 1998-11-25 2000-06-02 Cadus Pharmaceutical Corporation Methodes et compositions d'identification d'effecteurs de recepteurs
MX343200B (es) 1998-11-27 2016-10-19 Ucb Pharma Sa Composiciones y metodos para aumentar la mineralizacion ósea.
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6599692B1 (en) * 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6453242B1 (en) * 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US7013219B2 (en) * 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6504008B1 (en) 1999-02-01 2003-01-07 Cadus Technologies, Inc. Cell based signal generation
US20090130718A1 (en) * 1999-02-04 2009-05-21 Diversa Corporation Gene site saturation mutagenesis
EP1119368A2 (fr) 1999-03-03 2001-08-01 Biogen, Inc. Methodes de modulation du metabolisme et du stockage lipidiques
WO2000054814A1 (fr) * 1999-03-18 2000-09-21 Phylogeny, Inc. Methodes de recherche de composes utiles a la regulation de la proliferation cellulaire
US7030215B2 (en) * 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
DK2385124T3 (da) 1999-05-14 2013-11-18 Arbor Vita Corp Peptider, eller peptid-analoger, til modulering af bindingen af et PDZ protein og et PL protein
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US7396905B1 (en) 1999-05-21 2008-07-08 Mckeon Frank Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
US6555325B1 (en) * 1999-06-14 2003-04-29 Cadus Technologies, Inc. System for detection of a functional interaction between a compound and a cellular signal transduction component
WO2001007465A1 (fr) * 1999-07-22 2001-02-01 Smithkline Beecham Corporation Ga1R
US7223533B2 (en) 1999-09-10 2007-05-29 Cadus Technologies, Inc. Cell surface proteins and use thereof as indicators of activation of cellular signal transduction pathways
US8168178B2 (en) * 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
CA2394850C (fr) * 1999-12-06 2012-02-07 Sangamo Biosciences, Inc. Procede d'utilisation de banques de proteines a doigt de zinc randomisees, pour l'identification d'une fonction de genes
WO2001053480A1 (fr) * 2000-01-24 2001-07-26 Sangamo Biosciences, Inc. Polypeptides a liaison acide nucleique caracterises par des modules a liaison acide nucleique lies par une liaison flexible
US20020061512A1 (en) * 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
US6632645B1 (en) * 2000-03-02 2003-10-14 Promega Corporation Thermophilic DNA polymerases from Thermoactinomyces vulgaris
US6436677B1 (en) * 2000-03-02 2002-08-20 Promega Corporation Method of reverse transcription
US20030129724A1 (en) * 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
EP1278767A4 (fr) 2000-04-12 2003-11-12 Principia Pharmaceutical Corp Proteines fusionnees a l'albumine
MXPA02010907A (es) * 2000-05-05 2004-09-06 Gtc Biotherapeutics Inc Decorina producida transgenicamente.
WO2001087958A2 (fr) * 2000-05-16 2001-11-22 Thomas Jefferson University Structure cristalline de nitfhit en serpentin revelant qu'un tetramere de nit se lie a deux dimeres de fhit
US6573370B1 (en) * 2000-05-19 2003-06-03 Regents Of The University Of Michigan PON3 and uses thereof
EP1157999A1 (fr) * 2000-05-24 2001-11-28 Introgene B.V. Méthodes et moyens pour améliorer la transplantation de la peau en utilisant des vecteurs d'apport de genes munis d'un tropisme pour des fibroblastes primaires ainsi que d'autres utilisations de celles-ci
CN1444654A (zh) 2000-06-28 2003-09-24 梅德维特科学股份有限公司 新型治疗分子变体及其用途
US6878861B2 (en) * 2000-07-21 2005-04-12 Washington State University Research Foundation Acyl coenzyme A thioesterases
DE60140773D1 (de) 2000-08-18 2010-01-21 Dyax Corp Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
US20040033605A1 (en) * 2000-09-20 2004-02-19 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells
US7235233B2 (en) * 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
EP1366160B1 (fr) * 2000-10-06 2008-07-09 The Regents Of The University Of Michigan Sequences peptidiques et d'acides nucleiques de mini-dystrophine
US7045283B2 (en) 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
US7060442B2 (en) * 2000-10-30 2006-06-13 Regents Of The University Of Michigan Modulators on Nod2 signaling
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7026462B2 (en) * 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US20020150895A1 (en) * 2000-12-22 2002-10-17 Raymond Wheeler Method and apparatus for filtering and extending RNA alignment coverage
US7445802B2 (en) * 2000-12-26 2008-11-04 Yeda Research And Development Co. Ltd Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
KR100810527B1 (ko) * 2001-01-15 2008-03-10 한국생명공학연구원 유전자 담체 표면 전시방법
DK1353941T3 (da) * 2001-01-22 2013-06-17 Sangamo Biosciences Inc Modificerede zinkfingerbindingsproteiner
US7067617B2 (en) * 2001-02-21 2006-06-27 The Scripps Research Institute Zinc finger binding domains for nucleotide sequence ANN
US6849449B2 (en) * 2001-03-01 2005-02-01 Regents Of The University Of Michigan Orphanin FQ receptor nucleic acids
JP4343534B2 (ja) 2001-03-02 2009-10-14 ゲーペーツェー バイオテック アクチェンゲゼルシャフト ３ハイブリッド・アッセイ・システム
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
WO2002091248A1 (fr) * 2001-05-04 2002-11-14 Therma-Wave, Inc. Systemes et procedes de recette metrologique et de production de modele
ATE405586T1 (de) 2001-05-08 2008-09-15 Darwin Molecular Corp Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
EP1423428B2 (fr) * 2001-06-20 2012-11-14 Fibron Ltd. Anticorps bloquant l'activation de fgfr3, procedes de criblage et utilisations associes
AU2002336373A1 (en) * 2001-08-20 2003-03-03 The Scripps Research Institute Zinc finger binding domains for cnn
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
CA2459133A1 (fr) * 2001-09-28 2003-04-10 Selectx Pharmaceuticals, Inc. Procedes permettant de produire, selectionner et identifier des composes fixant une molecule cible
ES2556338T3 (es) 2001-10-10 2016-01-15 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
CA2471777A1 (fr) * 2001-12-18 2003-06-26 Endocube Sas Nouvelles proteines associees a la mort, et mecanismes d'action de thap1 et para4 dans la maitrise de l'apoptose
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
US20040009498A1 (en) * 2002-01-14 2004-01-15 Diversa Corporation Chimeric antigen binding molecules and methods for making and using them
US7262054B2 (en) * 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
WO2003062794A2 (fr) * 2002-01-24 2003-07-31 Breslin, John Procede d'utilisation des spectres de perturbation ou d'absorption electromagnetique pour diagnostiquer et detecter des anomalies dans des cellules, des tissus et des organismes
US7255986B2 (en) * 2002-01-31 2007-08-14 The Board Of Trustees Operating Michigan State University Compositions for the diagnosis and treatment of epizootic catarrhal enteritis in ferrets
WO2003070823A2 (fr) 2002-02-20 2003-08-28 The General Hospital Corporation Conjugues contenant un polymere biodegradable, et leurs utilisations
WO2003076455A2 (fr) 2002-03-05 2003-09-18 Ramot At Tel-Aviv University Ltd. Composition immunisante et procede permettant d'induire une reponse immunitaire contre le site de clivage de $g(b)-secretase
US20030186221A1 (en) * 2002-04-02 2003-10-02 Lockhart David J. Phage display affinity filter and forward screen
MXPA04008891A (es) * 2002-04-25 2004-11-26 Crucell Holland Bv Medios y metodos para la produccion de vectores de adenovirus.
WO2003095611A2 (fr) 2002-05-10 2003-11-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Gene pmepa1 regule par les androgenes et procedes d'utilisation de ce dernier pour inhiber la croissance des cellules cancereuses
US7455988B2 (en) * 2002-05-29 2008-11-25 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
CA2490004A1 (fr) * 2002-06-20 2003-12-31 Board Of Trustees Operating Michigan State University Division plastidique, genes et proteines correspondants ainsi que procedes d'utilisation
CA2493007A1 (fr) * 2002-07-19 2004-01-29 Cellzome Ag Complexes proteiques de la proteine activatrice de la transcription de tip60
AU2003256912A1 (en) 2002-08-16 2004-03-03 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
CN102023220A (zh) 2002-09-09 2011-04-20 生命树股份有限公司 诊断宫颈癌的方法
US20050202438A1 (en) * 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
WO2004022593A2 (fr) * 2002-09-09 2004-03-18 Nautilus Biotech Evolution rationnelle de cytokines pour une plus grande stabilite, les cytokines et molecules d'acide nucleique codant
US6863731B2 (en) * 2002-10-18 2005-03-08 Controls Corporation Of America System for deposition of inert barrier coating to increase corrosion resistance
EP1552025A4 (fr) * 2002-10-18 2006-12-13 Cylene Pharmaceuticals Inc Procedes servant a identifier des molecules antivirales ciblees vers des structures quadruplex
AU2003300817A1 (en) 2002-11-21 2004-06-18 Celltech R And D, Inc. Modulating immune responses
MXPA05010773A (es) 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
US7173010B2 (en) * 2003-05-19 2007-02-06 Regents Of The University Of Michigan Orphanin FQ receptor
US7655833B2 (en) * 2003-05-29 2010-02-02 Brookhaven Science Associates, Llc ADS genes for reducing saturated fatty acid levels in seed oils
IL156495A0 (en) * 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
CA2526847C (fr) * 2003-06-20 2011-01-25 Ambit Biosciences Corporation Dosage et kits servant a detecter une liaison proteique
DK1670903T3 (da) * 2003-09-05 2008-01-02 Cellzome Ag Behandling af neurodegenerative sygdomme
US7576052B2 (en) 2003-10-17 2009-08-18 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US7329725B1 (en) * 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
US20070280927A1 (en) * 2004-01-29 2007-12-06 Cellzome Ag Treatment Of Neurodegenerative Diseases By The Use Of Atp7a
EP1713501B1 (fr) * 2004-01-29 2008-01-16 Cellzome Ag Traitement de maladies neurodegeneratives au moyen de gpr49
US7432057B2 (en) * 2004-01-30 2008-10-07 Michigan State University Genetic test for PSE-susceptible turkeys
ATE498010T1 (de) 2004-03-01 2011-02-15 Immune Disease Inst Inc Natürliche igm-antikörper und inhibitoren davon
EP1732649B1 (fr) * 2004-03-26 2010-01-20 Cellzome Ag Traitement de maladies neurodegeneratives au moyen de la laptm4b
US8470315B2 (en) * 2004-04-13 2013-06-25 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
DK1745144T3 (da) 2004-05-11 2011-02-07 Axiogenesis Ag Analysefremgangsmåde til opsporing af lægemidler på grundlag af in vitro-differentierede celler
EP2314617B1 (fr) 2004-07-23 2015-06-24 Acceleron Pharma Inc. Polypeptides du récepteur ActRII
DE602004013202T2 (de) * 2004-08-09 2009-05-28 Cellzome Ag Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren
US8067008B2 (en) 2004-08-23 2011-11-29 Yeda Research And Development Co. Peptide inhibitors for mediating stress responses
EP1784220B1 (fr) 2004-08-26 2017-12-20 The University Of Western Ontario Cibles bacteriennes d'acquisition de fer
WO2006034455A2 (fr) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Composes de polypeptides pour l'inhibition de l'angiogenese et de croissance tumorale
GB0423871D0 (en) 2004-10-27 2004-12-01 Domantis Ltd Method
WO2006048877A2 (fr) * 2004-11-04 2006-05-11 Fibron Limited Traitement des pathologies malignes du lymphocyte b
US7939267B2 (en) * 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
SG171690A1 (en) 2005-03-22 2011-06-29 Harvard College Treatment of protein degradation disorders
US8034902B2 (en) * 2005-05-04 2011-10-11 Quark Pharmaceuticals, Inc. Recombinant antibodies against CD55 and CD59 and uses thereof
US20060281670A1 (en) * 2005-06-10 2006-12-14 Wisconsin Alumni Research Foundation (Warf) Compositions and methods for modulating angiogenesis
CA2617539A1 (fr) * 2005-07-01 2007-01-11 Washington University In St. Louis Anticorps des recepteurs de chimiokines phosphospecifiques
US20070026012A1 (en) 2005-08-01 2007-02-01 Cornell Research Foundation, Inc. Compositions and methods for monitoring and altering protein folding and solubility
WO2007056113A2 (fr) * 2005-11-02 2007-05-18 Cylene Pharmaceuticals, Inc. Procedes de ciblage de sequences quadruplex
EA015105B1 (ru) 2005-11-23 2011-06-30 Акселерон Фарма Инк. Антагонисты активина - actriia и их применение для стимулирования роста кости
WO2007062422A2 (fr) * 2005-11-28 2007-05-31 The Scripps Research Institute Domaines liant des doigts de zinc pour le triplet tnn
US20070154989A1 (en) * 2006-01-03 2007-07-05 The Scripps Research Institute Zinc finger domains specifically binding agc
WO2007106603A2 (fr) * 2006-01-06 2007-09-20 The Scripps Research Institute Marquage specifique de proteines a l'aide de doigts de zinc et utilisation de proteines marquees par des doigts de zinc a des fins d'analyse
JP5441416B2 (ja) 2006-02-14 2014-03-12 プレジデント アンド フェロウズ オブ ハーバード カレッジ 二官能性ヒストンデアセチラーゼインヒビター
US8383855B2 (en) 2006-02-14 2013-02-26 President And Fellows Of Harvard College Histone deacetylase inhibitors
CA2654540C (fr) * 2006-05-03 2017-01-17 President And Fellows Of Harvard College Inhibiteurs d'histone desacetylases et de tubuline desacetylases
EP2046384A4 (fr) * 2006-06-15 2009-12-02 Fibron Ltd Anticorps bloquant l'activation du récepteur du facteur de croissance des fibroblastes et leurs procédés d'utilisation
US8840882B2 (en) * 2006-06-23 2014-09-23 Quintessence Biosciences, Inc. Modified ribonucleases
WO2008005290A2 (fr) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Procédés de test d'agents anti-thrombotiques
US7977535B2 (en) 2006-07-12 2011-07-12 Board Of Trustees Of Michigan State University DNA encoding ring zinc-finger protein and the use of the DNA in vectors and bacteria and in plants
US8298801B2 (en) 2006-07-17 2012-10-30 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
JP2008044926A (ja) * 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
WO2008073160A2 (fr) * 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Procédés de conversion ou d'induction d'une immunité protectrice
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
KR100812110B1 (ko) * 2006-10-24 2008-03-12 한국과학기술원 징크 핑거 단백질과 원핵 생물의 전사 인자를 포함하는인공 전사 인자의 제조 및 이의 이용
EP3181580A1 (fr) 2006-11-02 2017-06-21 Acceleron Pharma Inc. Antagonistes des récepteurs alk1 et ligands et leurs utilisations
NZ577847A (en) 2006-12-18 2012-06-29 Acceleron Pharma Inc Activin-actrii antagonists and uses for increasing red blood cell levels
EP2629094A1 (fr) 2007-01-24 2013-08-21 Carnegie Mellon University Biocapteurs optiques
CN107050424A (zh) 2007-02-01 2017-08-18 阿塞勒隆制药公司 活化素‑actriia拮抗剂及在治疗或预防乳腺癌中的用途
EP2481415B1 (fr) 2007-02-09 2019-09-11 Acceleron Pharma Inc. Compositions comprenant des antagonistes Activin-ActRIIA
US20100077496A1 (en) * 2007-04-20 2010-03-25 Mt. Sinai School Of Medicine MO-1, A Gene Associated With Morbid Obesity
EP2155910A4 (fr) * 2007-05-08 2010-06-02 Univ Duke Compositions et procédés permettant de caractériser et de réguler une sensation olfactive
US8097422B2 (en) 2007-06-20 2012-01-17 Salk Institute For Biological Studies Kir channel modulators
WO2009036188A2 (fr) 2007-09-11 2009-03-19 University Of Massachusetts Protéine 7 de liaison au facteur de croissance similaire à l'insuline pour le traitement du cancer
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
WO2009048909A1 (fr) * 2007-10-08 2009-04-16 Quintessence Biosciences, Inc. Compositions et procédés pour des thérapies à base de ribonucléase
US20110038924A1 (en) * 2007-10-29 2011-02-17 Goomer Randal S Osteoarthritis gene therapy
KR20190037355A (ko) 2008-05-02 2019-04-05 악셀레론 파마 인코포레이티드 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 ａｌｋ１ 길항제 기재의 방법 및 조성물
AU2009242486B2 (en) 2008-05-02 2013-10-10 Cellscript, Inc. RNA polyphosphatase compositions, kits, and uses thereof
US8815807B2 (en) 2008-06-03 2014-08-26 President And Fellows Of Harvard College Peptides and peptide compositions having osteoinductive activity
WO2009156994A1 (fr) * 2008-06-24 2009-12-30 Hadasit Medical Research Services And Development Ltd. Anticorps spécifiques de ccl20 pour la thérapie du cancer
JP5778576B2 (ja) 2008-06-26 2015-09-16 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａアンタゴニストを投薬する方法および処置される患者をモニターする方法
AU2009262968A1 (en) 2008-06-26 2009-12-30 Acceleron Pharma Inc. Antagonists of activin-ActRIIa and uses for increasing red blood cell levels
KR101708946B1 (ko) 2008-07-23 2017-02-21 다나-파버 캔서 인스티튜트 인크. 탈아세틸화제 억제제 및 그것의 용도
WO2010039985A1 (fr) 2008-10-01 2010-04-08 Quintessence Biosciences, Inc. Ribonucléases thérapeutiques
EP2391714B2 (fr) 2009-01-30 2019-07-24 Whitehead Institute for Biomedical Research Procédés de ligature et utilisations associées
JP2012518072A (ja) 2009-02-18 2012-08-09 カーネギー メロン ユニバーシティ 明検出のためのクエンチャー付加デンドリマー色素
JP5755635B2 (ja) 2009-03-30 2015-07-29 アクセルロン ファーマ， インコーポレイテッド Ｂｍｐ−ａｌｋ３アンタゴニストおよび骨成長促進のためのその使用
WO2010148010A1 (fr) 2009-06-15 2010-12-23 4S3 Bioscience Inc. Procédés et compositions pour le traitement de la myopathie myotubulaire mettant en oeuvre des polypeptides chimériques comprenant des polypeptides de myotubularine (mrm1)
WO2011019393A2 (fr) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Inhibiteurs de hdac classe- et isoforme-spécifiques et utilisations de ceux-ci
US20110045053A1 (en) * 2009-08-18 2011-02-24 Shen Michael M Isolated population of luminal stem cells that give rise to prostate cancer and methods of using same
US8889394B2 (en) * 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
US20120263719A1 (en) 2009-10-22 2012-10-18 Yeda Research And Development Co., Ltd. Compositions and methods for treating aspergillosis
IL201999A (en) 2009-11-08 2017-10-31 Medical Res & Development Fund For Health Services Bnai Zion Medical Center The State Of Israel A knockout mouse of the 1 – mo gene, a gene associated with morbidly extreme obesity
BR112012013330A2 (pt) 2009-12-02 2017-03-28 Acceleron Pharma Inc composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
JP2013519392A (ja) 2010-02-16 2013-05-30 メディミューン，エルエルシー Ｈｓａ関連組成物および使用方法
EP2548030B1 (fr) 2010-03-18 2015-05-27 Cornell University Préparation d'anticorps correctement pliés utilisant la présentation sur la membrane intérieure d'intermédiaires de translocation twin-arginine
EP2577309B1 (fr) 2010-05-25 2016-11-23 Carnegie Mellon University Sondes ciblées de physiologie cellulaire
CN103370076A (zh) 2010-11-02 2013-10-23 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
CA2828002A1 (fr) 2011-03-03 2012-09-07 Quark Pharmaceuticals, Inc. Compositions et procedes pour traiter des maladies et des lesions pulmonaires
EP3549952A1 (fr) 2011-04-20 2019-10-09 Acceleron Pharma Inc. Polypeptides d'endogline et leurs utilisations
CA2836503C (fr) 2011-05-23 2020-09-22 Yeda Research And Development Co. Ltd. Utilisation de la phosphorylation d'akt en tant que biomarqueur pour le pronostic et le traitement de maladies neurodegeneratives
EP2750767A4 (fr) 2011-09-02 2015-10-14 Univ Columbia Inhibiteurs de camkii, ip3r, calcineurine, p38 et mk2/3 pour traiter des perturbations métaboliques de l'obésité
WO2013040504A2 (fr) 2011-09-14 2013-03-21 University Of Massachusetts Srpx dans le traitement du cancer
WO2013054320A1 (fr) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Anticorps dirigés contre la molécule d'adhésion cellulaire associée à l'antigène carcino-embryonnaire (ceacam)
CN104334191A (zh) 2012-03-29 2015-02-04 纽约市哥伦比亚大学托管会 治疗毛发脱落疾病的方法
WO2013150518A1 (fr) 2012-04-01 2013-10-10 Rappaport Family Institute For Research In The Medical Sciences Peptides d'inducteur de métalloprotéinase de matrice extracellulaire (emmprin) et anticorps de liaison
US9540439B2 (en) 2012-10-08 2017-01-10 St. Jude Children's Research Hospital Therapies based on control of regulatory T cell stability and function via a neuropilin-1:semaphorin axis
AU2013334659B2 (en) 2012-10-24 2019-07-11 Celgene Corporation Biomarker for use in treating anemia
HK1214504A1 (zh) 2012-10-24 2016-07-29 细胞基因公司 用於治療貧血的方法
EP3308796B1 (fr) 2012-11-02 2021-07-14 Celgene Corporation Antagonistes d'activine-actrii et utilisations pour le traitement de troubles osseux et autres
WO2014082096A1 (fr) 2012-11-26 2014-05-30 The Trustees Of Columbia University In The City Of New York Procédé pour la culture d'organoïdes de prostate humaine et murine et utilisations correspondantes
WO2015027082A1 (fr) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Variants de type ii du récepteur de tgf-bêta et utilisations associées
EA202090707A1 (ru) 2013-10-25 2020-12-30 Акселерон Фарма, Инк. Эндоглиновые пептиды для лечения фиброзных заболеваний
RU2697522C1 (ru) 2013-11-25 2019-08-15 СиСиЭйЭм БАЙОТЕРАПЬЮТИКС ЛТД. Композиции, содержащие анти-сеасам 1 и анти-pd антитела для терапии рака
CA2936102A1 (fr) 2014-01-13 2015-07-16 Valerion Therapeutics, Llc Fragment d'internalisation
US20170174764A1 (en) 2014-03-27 2017-06-22 Yeda Research And Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies
BR112016024319B1 (pt) 2014-04-18 2024-01-23 Acceleron Pharma Inc USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
WO2015166484A1 (fr) 2014-04-27 2015-11-05 Ccam Therapeutics Ltd. Anticorps humanisés dirigés contre ceacam1
BR112016028567A2 (pt) 2014-06-09 2018-01-30 Kyowa Hakko Kirin Co Ltd método para utilizar ligante anti-fgf23 e para tratar doença e/ou condição relacionada com fgf23 e para aumentar a remodelação óssea
BR112016029226A2 (pt) 2014-06-13 2017-10-17 Acceleron Pharma Inc métodos e composições para o tratamento de úlceras
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
US10434177B2 (en) 2014-11-17 2019-10-08 Carnegie Mellon University Activatable two-component photosensitizers
TWI773117B (zh) 2014-12-03 2022-08-01 美商西建公司 活化素-actrii拮抗劑及治療貧血之用途
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
WO2016123454A1 (fr) 2015-01-29 2016-08-04 Board Of Trustees Of Miching State University Polypeptides cryptiques et leurs utilisations
WO2016164503A1 (fr) 2015-04-06 2016-10-13 Acceleron Pharma Inc. Hétéromultimères alk7:actriib et leurs utilisations
AU2016246602B2 (en) 2015-04-06 2020-11-19 Acceleron Pharma Inc. Single-arm type I and type II receptor fusion proteins and uses thereof
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
US20180156807A1 (en) 2015-04-29 2018-06-07 New York University Method for treating high-grade gliomas
CA2994413A1 (fr) 2015-08-04 2017-02-09 Acceleron Pharma, Inc. Procedes de traitement de syndrome myeloproliferatif
EP4218833A1 (fr) 2015-10-01 2023-08-02 Whitehead Institute for Biomedical Research Marquage d'anticorps
EP3362093A4 (fr) 2015-10-13 2019-05-08 Technion Research & Development Foundation Limited Anticorps monoclonaux neutralisant l'héparanase
EP3370754A4 (fr) 2015-11-04 2019-10-23 Acceleron Pharma Inc. Méthodes pour augmenter les taux d'érythrocytes et traiter l'érythropoïèse inefficace
AU2016359695A1 (en) 2015-11-23 2018-06-14 Acceleron Pharma Inc. Methods for treating eye disorders
EP3439741A4 (fr) 2016-04-06 2020-05-06 Acceleron Pharma Inc. Antagonistes d'alk7 et leurs utilisations
MD3496739T2 (ro) 2016-07-15 2021-09-30 Acceleron Pharma Inc Compoziții care cuprind polipeptide actriia pentru utilizarea în tratarea hipertensiunii pulmonare
PT3490582T (pt) 2016-07-27 2024-08-21 Acceleron Pharma Inc Composições para utilização no tratamento da mielofibrose
EP4026556B1 (fr) 2016-10-05 2025-07-30 Acceleron Pharma Inc. Compositions destinées à être utilisées dans le traitement de la fibrose rénale dans les maladies du rein
CN106725834B (zh) * 2016-12-30 2023-11-07 重庆西山科技股份有限公司 自动识别射频手柄及射频操作组件
DK3628049T3 (da) 2017-05-04 2023-08-14 Acceleron Pharma Inc Tgf-beta-receptortype-ii-fusionsproteiner og anvendelser deraf
HRP20241477T1 (hr) 2017-06-14 2025-01-03 Celgene Corporation Postupci liječenja mijeloproliferativne neoplazme povezane s mijelofibrozom i anemijom
JP7654402B2 (ja) 2018-02-09 2025-04-01 アクセルロン ファーマ インコーポレイテッド 異所性骨化を処置するための方法
WO2020006108A2 (fr) 2018-06-26 2020-01-02 Duke University Récepteurs odorants synthétiques
JP2023529892A (ja) 2020-06-09 2023-07-12 イノザイム ファーマ インク． 可溶性ｅｎｐｐ１又はｅｎｐｐ３タンパク質及びその使用
CA3217862A1 (fr) 2021-05-05 2022-11-10 Radius Pharmaceuticals, Inc. Modele animal ayant une recombinaison homologue du recepteur pth1 de souris

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631257A (en) * 1978-12-26 1986-12-23 Cetus Corporation Stable high copy number plasmids
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US4506013A (en) * 1980-10-03 1985-03-19 Eli Lilly And Company Stabilizing and selecting recombinant DNA host cells
US4568640A (en) * 1981-05-11 1986-02-04 Harvey Rubin Method of inserting amino acid analogs into proteins
US4732847A (en) * 1981-06-09 1988-03-22 University Of Hawaii Monoclonal antibodies for DNA-RNA hybrid complexes and their uses
US4650761A (en) * 1981-11-27 1987-03-17 Eli Lilly And Company Method for stabilizing and selecting recombinant DNA containing host cell
US4436815A (en) * 1981-11-27 1984-03-13 Eli Lilly And Company Method for stabilizing and selecting recombinant DNA containing host cells
US4656134A (en) * 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
EP0088994B1 (fr) * 1982-03-15 1991-06-19 Schering Corporation ADN hybride, composition liante produite à l'aide de celui-ci et procédés pour la mise en oeuvre
US4556643A (en) * 1982-07-26 1985-12-03 Agracetus Assay method and probe for polynucleotide sequences
US4637980A (en) * 1983-08-09 1987-01-20 Smithkline Beckman Corporation Externalization of products of bacteria
US4748119A (en) * 1983-09-19 1988-05-31 Alexander Rich Process for altering and regulating gene expression
EP0136907A3 (fr) * 1983-10-03 1986-12-30 Genentech, Inc. Système de contrôle d'expression xenogénésiaque, méthode pour son utilisation, vecteurs d'expression le contenant, cellules transformées par ceux-ci et protéines hétérologues produites par ceux-ci
US4665184A (en) * 1983-10-12 1987-05-12 California Institute Of Technology Bifunctional molecules having a DNA intercalator or DNA groove binder linked to ethylene diamine tetraacetic acid
US4777129A (en) * 1983-12-12 1988-10-11 Molecular Diagnostics, Inc. Nucleic acid probe detectable by specific nucleic acid binding protein
GB8334498D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Compounds
GB2166743B (en) * 1984-11-13 1989-01-05 Solvay Process for a thermo-inducible gene expression in gram positive bacteria and bacillus subtilis strains containing plasmids which induce such an expression
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
WO1988006601A1 (fr) * 1987-03-02 1988-09-07 Genex Corporation Represseurs de genes
DE3852304T3 (de) * 1987-03-02 1999-07-01 Enzon Labs Inc., Piscataway, N.J. Organismus als Träger für "Single Chain Antibody Domain (SCAD)".
NL8700740A (nl) * 1987-03-30 1988-10-17 Solvay Operator dna, recombinante vector, getransformeerde cellen en organismen, gebruik van het operator dna.
EP0285123A3 (fr) * 1987-04-03 1989-02-01 Stabra AG Méthode de mutagénèse complète d'acides nucléiques

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Biochemistry, Volume 28, No. 23, Issued 1989, HUGHES et al., "Purification and Characterization of a protein from Hela cells that binds with high affinity to the estrogen response element, GGTCAGCGTGACC" See pages 9137-9142. *
Biological Abstracts Volume 85(9) Issued 01 May 1988 HAUBER et al. "Mutational analysis of the trans-activation responsive region of the human immunodeficiency virus type long terminal repeat" See reference 89626. *
Biological Abstracts Volume 87(4) Issued 15 February 1989 SWEDER et al. "Purification and characterization of proteins that bind to yeast ARSs" See ref. 37597. *
Journal of Virology Volume 63(6) Issued June 1989 HARRICH et al. "Role of SPI-binding domains in the in vivo transcriptional regulation of the human immunodeficiency virus type 1 long terminal repeat" See pages 2585-2591. *
Lif Sciences Collection Accession Number 82001901798 Issued 1988 "Purification of the human immunodeficiency virus type 1 enhancer and TAR binding proteins EBP-1 and UBP-1". See Abstract. *
Life Sciences Collection Accession Number 82001774133 Issued 1988 HENDERSON "Isolation and characterization of a novel protein (X-ORF) product from ISIV and HIV-2". See Abstract. *
Proceedings of the National Academy of Sciences USA Volume 85 issued December 1988 GAYNOR et al. "Repeated B motifs in the human immunodeficiency virus type I long terminal repeat enhancer region do not exhibit cooperative factor binding" See pages 9406-9410. *

Also Published As

Publication number Publication date
US5096815A (en) 1992-03-17
EP0452413A1 (fr) 1991-10-23
CA2045516A1 (fr) 1990-07-07
DE69033506D1 (de) 2000-05-18
AU4958890A (en) 1990-08-13
EP0452413B1 (fr) 2000-04-12
IL92957A0 (en) 1990-09-17
WO1990007862A2 (fr) 1990-07-26
ATE191746T1 (de) 2000-04-15
EP0452413A4 (en) 1992-06-03
JPH04504052A (ja) 1992-07-23

Similar Documents

Publication Publication Date Title
WO1990007862A3 (fr) Production et selection de proteines et de polypeptides nouveaux de liaison a l'adn
RU94045919A (ru) Антитела, клетки, полипептид, днк векторы, способ получения полипептида, способ получения антитела, фармацевтическая композиция
ATE515569T1 (de) Peptidnucleinsäuren
AU539535B2 (en) Recombinant dna molecules
EP2014770A3 (fr) Polypeptide secrété à induction par WNT-1 WISP-2
DE69324359D1 (de) Verbessertes verfahren zur herstellung von endotoxinbindungsproteinen
EP0175360A3 (fr) Anticorps contre les peptides et leurs utilisation dans la détection des produits d'oncogènes
PL231111A1 (en) Dna sequences,molecules of dna recombinants and methodsof preparing of polypeptides of specifity of antigens of virus foot-and-mouth disease
Nichols et al. Sequences of RNA fragments from the bacteriophage f2 coat protein cistron which differ from their R17 counterparts
WO2001032882A3 (fr) Acides nucleiques et proteines provenant des streptocoques du groupe b
Kirsch et al. Cloning, High-Yield Expression inEscherichia coli, and Purification of Biologically Active HIV-1 Tat Protein
FI850814A7 (fi) Proteiineja, farmaseuttisia seoksia, geenejä, vektoreita, isäntäorgan ismeja ja menetelmiä niiden tuottamiseksi.
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
Koldin et al. A comparison of the difterent DNA binding specificities of the bZip proteins C/EBP and GCN4
CA2390685A1 (fr) Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique
CA2467383A1 (fr) Proteines fluorescentes a maturation rapide et leurs methodes d'utilisation
WO2002012475A3 (fr) Facteur associe a c1q, polypeptides homologues et utilisations therapeutiques associees
Camara-Clayette et al. The E-box of the human glycophorin B promoter is involved in the erythroid-specific expression of the GPB gene
Iguchi-Ariga et al. Cloning of the p53-dependent origin of cellular DNA replication
WO2025222100A3 (fr) Protéines de liaison à cd3, acides nucléiques codant de telles protéines, et leurs procédés de préparation et d'utilisation
RU1575576C (ru) Рекомбинантна плазмидна ДНК р7,5S @ - S, кодирующа pReS @ - S ген вируса гепатита В, способ ее конструировани и штамм рекомбинантного вируса осповакцины, экспрессирующий pReS @ - S ген вируса гепатита В
EP1666594A3 (fr) Polypeptide, acides nucléiques le codant, et leur utilisation pour le diagnostic du cancer
WO2024231728A3 (fr) Analogues de spycatcher et leurs utilisations
Masahide et al. Constitutive and inducible factors bind to regulatory element 3 in the promoter of the gene encoding mouse granulocyte colony-stimulating factor
Gussin RNA phages, edited by Norton D. Zinder: Pp. 428.(Cold Spring Harbor Laboratory: Cold Spring Harbor, New York). $28.00

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH DE DK FI GB HU JP KP KR LK MC MG MW NL NO RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH DE DK FI GB HU JP KP KR LK MC MG MW NL NO RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2045516

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1990902453

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1990902453

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1990902453

Country of ref document: EP